Please login to the form below

Not currently logged in
Email:
Password:

tafenoquine

This page shows the latest tafenoquine news and features for those working in and with pharma, biotech and healthcare.

GSK cues up regulatory filings for relapsing malaria drug

GSK cues up regulatory filings for relapsing malaria drug

GSK cues up regulatory filings for relapsing malaria drug. 60% of patients on tafenoquine combination remained relapse-free for six months. ... A second trial called GATHER showed that there was little difference between tafenoquine and primaquine on

Latest news

  • Scientists finds new drug target for malaria Scientists finds new drug target for malaria

    Other drugs coming through development include GlaxoSmithKline's tafenoquine and Sanofi's OZ439 - both of which are aminoquinolines in phase II trials - and triazolopyrimidine candidate DSM265, which is being guided through

More from news
Approximately 1 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
HAVAS LYNX

Welcome to HAVAS LYNX, a leading global healthcare communications group....

Latest intelligence

EU
Innovation in merger control and the impact on the pharmaceutical sector
Is focusing on pipeline products enough to assess regulatory risks?...
Nudge-nudge, think-think
Chris Ross examines the personal complexities of human behaviour – and explains why fun, emotion and peer endorsement could be key to designing effective behavioural change programmes...
Peoples Award
Quality in Care Diabetes 2018: the best in innovative diabetes care
Awards highlight new evidence-based approaches to improving care...

Infographics